The reading room / Peptide research blog

Peptide research, explained.

Detailed guides to peptide identity, biological pathways, analytical methods and clinical evidence. Search the reading room or follow a research topic.

Browse 13 research topics
Reset filters

All guides & articles

109–120 of 149 guides

Page 10 of 13
PRRT research dossier with targeting, clinical-context and outcomes document dividers under a brass magnifier.Peptide Fundamentals

PRRT Half-Life: What It Means in Peptide Receptor Therapy

In peptide receptor radionuclide therapy (PRRT), half-life can describe radioactive decay, biological clearance or both. Learn how those meanings differ.

Updated 2026-11-05 ↗
Isolated follicle teaching specimen in a specimen dish and a human scalp teaching model, with independent laboratory and human-study evidence archives, in the Peptides for Hair Growth research file.Research Practice

Peptides for Hair Growth: Follicle Models vs Human Outcomes

A hair follicle growing in an ex vivo experiment is not the same outcome as improved scalp hair density in a controlled human study.

Updated 2026-10-29 ↗
Detailed skeletal-muscle cross-section teaching specimen, a calibrated strength-measurement instrument without numerical results and a DXA evidence sleeve, in the Peptides for Muscle Growth research file.Research Practice

Peptides for Muscle Growth: What the Evidence Measures

Peptides for muscle growth are often discussed through hormone responses or increases in lean mass. Neither is the same as measured muscle strength or physical function.

Updated 2026-10-29 ↗
Petrelintide amylin-analogue identity card and study-protocol envelopes under a magnifier focused on endpoint definitions.Research Practice

Petrelintide: Reading the New Amylin Research

Petrelintide is a long-acting amylin analogue being investigated through molecular-design and human clinical studies.

Updated 2026-10-29 ↗
Amylin research index slip and a gastric-function teaching specimen with an independent Pramlintide study folder.Peptide Fundamentals

Pramlintide: Understanding Amylin Beyond the GLP-1 Headlines

Pramlintide is an amylin analogue with a product-specific role alongside mealtime insulin. Its evidence should not be read as a generic weight-loss-peptide comparison.

Updated 2026-10-29 ↗
Three-compartment target-system archive tray GIP, GLP-1, GCGR for Retatrutide and a two-compartment GIP, GLP-1 tray for Tirzepatide, in the Retatrutide vs Tirzepatide research file.Research Practice

Retatrutide vs Tirzepatide: Receptors, Trials and Fair Comparisons

Retatrutide and tirzepatide differ in receptor-related design and in the clinical programs available for comparison.

Updated 2026-10-29 ↗
Empty clear drinking glass and two trial-population file packets, arranged as a comparative evidence investigation, in the Semaglutide and Alcohol Craving research file.Research Practice

Semaglutide and Alcohol Craving: The Trials Do Not All Say the Same Thing

Semaglutide alcohol-use research contains promising findings and results that resist a simple headline.

Updated 2026-10-29 ↗
cutaway eye teaching specimen with a detachable retinal vessel insert illuminated by a desk lamp, in a Retinopathy safety-file setting, in the Semaglutide and Diabetic Retinopathy research file.Research Practice

Semaglutide and Diabetic Retinopathy: Reading the Safety Signal

The semaglutide retinopathy signal arose from a defined complication endpoint in SUSTAIN 6, a cardiovascular trial involving people with type 2 diabetes at high cardiovascular risk.

Updated 2026-10-29 ↗
kidney cross-section teaching specimen with a magnifying glass revealing glomerular detail, on a FLOW case folio, in the Semaglutide and Kidney Disease research file.Research Practice

Semaglutide and Kidney Disease: What the FLOW Trial Found

FLOW studied adults with type 2 diabetes and chronic kidney disease. Its 24% lower hazard concerned a composite of major kidney events and kidney-related or cardiovascular death.

Updated 2026-11-15 ↗
Three-dimensional heart teaching specimen half-exposed from a defined-population archive box, with heading SELECT and a Population evidence tag, in the Semaglutide and Heart Outcomes research file.Research Practice

Semaglutide and Heart Outcomes: The SELECT Population Matters

SELECT tested a cardiovascular question in adults with established cardiovascular disease and overweight or obesity, without diabetes.

Updated 2026-10-29 ↗
Two study-intervention packets Semaglutide and Tirzepatide inside a single shared head-to-head trial binder, a heavy binder clamp visually unites them, in the Semaglutide vs Tirzepatide research file.Research Practice

Semaglutide vs Tirzepatide: What Head-to-Head Evidence Shows

SURMOUNT-5 directly compared tirzepatide with semaglutide for weight management in adults with obesity without type 2 diabetes.

Updated 2026-10-29 ↗
Heavy mechanical clinical body-weight scale photographed empty, with a long Maintenance archive divider crossing a research file, in the Semaglutide Weight-Loss Plateau research file.Research Practice

Semaglutide Weight Loss Plateau: What the Trials Show

In STEP 5, average semaglutide weight loss leveled off around week 60 and was maintained through week 104. A plateau does not by itself mean treatment has stopped working.

Updated 2026-11-15 ↗
Peptide Research Guides & Evidence: Page 10 | PeptideTwo